Table 4.
Health-related quality of life (HRQoL) according to the European Organisation for Research and Treatment of Cancer (EORTC) QLQ-C30 and the disease-specific EORTC BLS24 (at baseline) and BLM30 (at follow-up) in 107 patients undergoing radical cystectomy at Aarhus University Hospital, 2011–2013.
| Intervention Difference % (95% CI) Follow-up to baseline nI=50 | Standard Difference % (95% CI) Follow-up to baseline nS=57 | Difference (95% CI) | P-value | |
|---|---|---|---|---|
| Overall HRQoL (score 0–100), % | ||||
| Global health status | 1.8 (−5.2 to 8.7) | 4.2 (−4.0 to 12.3) | −2.4 (−13.2 to 8.4) | 0.60 |
| Functional scales (score 0–100), % | ||||
| Physical functioning | −6.8 (−13.3 to −0.4) | −4.4 (−7.9 to −0.9) | −2.4 (−9.3 to 4.6) | 0.59 |
| Role functioning | −10.2 (−23.3 to 2.9) | 0.3 (−10.4 to −10.9) | −10.5† (−26.9 to −5.9) | 0.11 |
| Emotional functioning | 7.1 (−0.5 to 14.8) | 11.3 (5.7–16.9) | −4.2† (−13.4 to 5.0) | 0.35 |
| Cognitive functioning | −4.4 (−12.0 to 3.0) | 1.6 (−5.3 to 3.2) | −6.1† (−14.6 to 3.0) | 0.37 |
| Social functioning | −7.3 (−15.2 to 0.6) | −5.9 (−11.7 to −0.1) | −1.4 (−10.9 to 8.0) | 0.93 |
| Symptom scales (score 0–100), % | ||||
| Fatigue | 7.3 (−2.5 to 17.2) | 0.9 (−5.9 to 7.7) | 6.5† (−5.0 to 17.9) | 0.18 |
| Nausea and vomiting | 0.8 (−7.1 to 8.7) | 7.5 (−3.9 to 3.9) | 0.8 (−7.5 to 9.1) | 0.36 |
| Pain | 0.8 (−9.8 to 11.4) | −1.3 (−7.8 to 5.2) | 2.1 (−9.7 to 13.9) | 0.73 |
| Dyspnea | −7.0 (−15.5 to 1.6) | 2.6 (−4.4 to 9.6) | −9.6† (−20.4 to −1.2) | 0.05* |
| Insomnia | 6.4 (−4.5 to 17.2) | −7.8 (−17.4 to 1.6) | 14.2† (0.1–28.3) | 0.04* |
| Appetite loss | 0.8 (−9.4 to 10.9) | −2.0 (−11.2 to 7.3) | 2.7 (−10.8 to 16.3) | 0.78 |
| Constipation | 1.6 (5.7–8.8) | 14.4 (6.4–22.4) | −12.8† (−23.7 to −1.9) | 0.02* |
| Diarrhea | 1.6 (7.3–10.5) | 0.6 (1.0–7.3) | 0.9 (−9.8 to 11.7) | 0.81 |
| Disease-specific scales (BLM30, BLS24, score 0–100), % | ||||
| Future perspectives (worries) | −26.6 (−35.6 to −17.6) | −29.3 (−37.7 to 20.9) | 2.7 (−9.4 to 14.8) | 0.55 |
| Abdominal flatulence | 4.3 (−3.6 to 12.1) | 10.7 (3.0–18.3) | −6.4† (−17.4 to −4.4) | 0.05* |
| Sexual interest | 2.0 (−9.0 to 13.6) | −5.3 (−11.7 to 1.2) | 7.3† (−4.9 to 19.7) | 0.16 |
| Sexual activity | −4.4 (−15.0 to 6.9) | −10.5 (−18.2 to −2.8) | 7.4 (−6.4 to 19.4) | 0.47 |
| Single time point postsurgery (score 0–100), % | ||||
| Body image | 28.9 (19.7–37.9) | 19.1 (12.6–25.5) | 9.8† (−0.9 to 20.5) | 0.11 |
| Urinary problems (only neobladders) | 18.1 (5.3–30.9) | 38.3 (19.4–57.0) | −20‡ (−40.4 to 0) | 0.05* |
| Catheter problems (only neobladders) | 38.8 (−2.0 to 79.8) | 8.3 (−11.4 to 28.0) | 30.5‡ (−5.8 to 66.9) | 0.06 |
| Stoma problems (only ileal conduit) | 18.2 (12.75–23.8) | 13.5 (9.2–17.7) | 4.7† (−1.9 to 11.5) | 0.17 |
Notes: Increases in the function subscale scores represent an improvement in the HRQoL, whereas increases in the symptom subscale scores represent a deterioration. The null hypothesis was tested using the Wilcoxon signed-rank test.
*
P≤0.05;
†
clinically relevant difference in small–medium efficacy;
‡
clinically relevant difference in large efficacy.
Abbreviation: CI, confidence interval; QLQ-C30, Quality of Life Questionnaire Core 30.